Skip to content

Mapping individual routes of risk and risilience

Mapping individual routes of risk and risilience - MIRORR study: Mapping individual routes of risk and risilience

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON47218
Enrollment
175
Registered
2015-07-30
Start date
2015-12-01
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis proneness

Interventions

None listed

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All participants: - Are aged between 18 and 35 years - Read and speak Dutch fluently - Should be capable of following the research procedures - Provide Informed Consent;Participants subsample 1: - Are currently (i.e. at moment of screening) not in clinical care for mental health (e.g. GGZ, POH-GGZ, Psychologist);Participants subsample 2: - Are currently in clinical care for mental health - Have mild, non-psychotic psychopathology, as evidenced by a score below 6 on the Prodromal Questionnaire (PQ) ;Participants subsample 3: - Are currently in clinical care for mental health - Have mild psychopathology including subclinical psychotic symptoms, as evidenced by a score of or above 6 on the PQ, but are not at UHR for psychosis, as indexed by the Comprehensive Assessment of At Risk Mental State (CAARMS) ;Participants subsample 4: - Are currently in clinical care for mental health - Are at clinical high risk for psychosis, as indexed by the CAARMS

Exclusion criteria

Exclusion criteria: - History of or current psychotic episode, according to the DSM-IV criteria - Pregnancy - Significant hearing or visual problems impairments - No internet connection at home or on mobile phone or tablet

Design outcomes

Primary

MeasureTime frame
Network parameters of individuals in different clinical stages will be compared. These network parameters include the strength and directionality of symptom connections and centrality indices. Also, within-individual changes in these network parameters (from baseline to follow-up) will be linked to progression through clinical stages.

Secondary

MeasureTime frame
Please, see "primary study parameters" for the most important primary and secundary study parameters.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)